Supply Chain

Marathon Pharmaceuticals earned approval from the Food and Drug Administration for its drug Emflaza.

The Federal Trade Commision on Tuesday filed a complaint against Shire ViroPharma, claiming the drugmaker abused government processes to prevent generic competition of its antibiotic Vancocin HCl from hitting the market.

Kaléo is facing congressional scrutiny for the price of its naloxone delivery device Evzio, reports Fortune.

St. Jude Medical identified a new cybersecurity issue with its Merlin@home Trasmitter range only a month after fixing various security flaws in similar devices, reports ZDNet.

The U.S. Court of Appeals on Wednesday stayed an order that would bar Regeneron Pharmaceuticals and Sanofi from selling their cholesterol drug Praluent.The drugmakers can continue to sell the medication as they undergo the appeals process, reports Reuters.

Pharmacy benefit manufacturers — third-party companies that manage prescription benefits for health plans — are the newest players in the pharmaceutical industry facing backlash for high prescription drug prices, reports Bloomberg.

Biosimilar drugs are highly similar, although not exact, versions of biologic drugs. With a handful of these treatments already approved by the Food and Drug Administration — and dozens of others coming down the pipeline — biosimilars are poised to…

The Pew Agency for Charitable Trusts and the International Society for Pharmaceutical Engineers released a report exploring the relationship between manufacturing, supply chain and market forces — and how these contribute to drug shortages.

The medical technology industry workforce decreased by 28,834 jobs after the medical device excise tax took effect, reports the Advanced Medical Technology Association.

While President Donald Trump publicly called for CMS to negotiate drug prices, top pharmaceutical CEOs said he never brought up government intervention on pricing during a recent closed-door meeting on high drug costs, reports The Washington Post.